12 results about "Bone marrow sample" patented technology

The invention provides a use of a marker or a combination thereof in preparation of a product for prediction, diagnosis or auxiliary diagnosis of measurable residual diseases, the measurable residual diseases occur after clinical complete remission of acute myelogenous leukemia patients, and the marker or the combination thereof comprises a C-X-C chemokine receptor 4 gene. According to the method, a multi-parameter flow sorting technology is adopted, leukemia cell populations are separated from bone marrow samples of patients in the first diagnosis stage and the AML MRD stage, and a sufficient number of residual disease cells are successfully captured through a single cell transcriptome sequencing technology. The CXCR4 low-expression cell is identified to be capable of being used as a common marker of an MRD cell, and is verified in a clinical AML patient specimen. And an innovative scheme is provided for MRD monitoring of AML patients lacking clear molecular markers. And meanwhile, a CXCR4 low-expression cell is provided as a function substitution model of the MRD cell, so that the technical limitation of insufficient residual cells in the traditional research is broken through, and a reliable research system is established for systematically exploring the biological characteristics of the MRD cell.

The present invention refers to an in vitro method to determine simultaneously anti-cancer activity and hematotoxicity of an antibody-drug conjugate, comprising: (a) mixing a sample comprising cancer cells with a bone marrow sample; (b) adding an antibody-drug conjugate to the mixture of step (a); (c) determining anti-cancer activity of the antibody-drug conjugate by measuring cell depletion of tumor cells; and (d) determining hematotoxicity of the antibody-drug conjugate by measuring cell depletion of cells of the bone marrow sample.

The invention discloses a method for detecting 19 amino acids in brain tissue and bone marrow of a mouse. The method comprises the following steps: step 1, preparing a standard substance; step 2, sampling brain tissues and bone marrow of the mouse; step 3, removing proteins in brain tissues and bone marrow samples; step 4, preparing a derivatization reagent; step 5, separating and determining 19 amino acids in the brain tissue and the bone marrow sample by HPLC-FLD; and 6, calculating a result. The method for detecting 19 amino acids in brain tissues and bone marrow of mice has the advantages of simple operation steps, high accuracy and good sensitivity, and can realize accurate detection of 19 amino acids in brain tissues and bone marrow samples.

The present disclosure relates to computer-implemented methods for classifying cell neighborhoods in a bone marrow sample obtained from a subject suffering from multiple myeloma (MM) and for defining significant cell neighborhoods in that sample that are associated with treatment outcomes in subjects with MM who receive a T cell-redirecting therapy. Image processing systems that can be used to analyze bone marrow samples and identify cell neighborhoods are also provided. Moreover, methods for predicting a treatment response to a T cell-redirecting therapy in a subject suffering from MM are disclosed.

This utility model discloses a bone aspiration sampling needle, belonging to the field of medical devices. One end of the outer needle body is serrated, and an axial sample receiving cavity is provided inside the outer needle. One end of the inner needle body is equipped with a drill bit. The inner needle body is detachably fitted into the sample receiving cavity, with the drill bit extending out of the serrated end of the sample receiving cavity. The outer wall of the inner needle body fits against the inner wall of the serrations. After the drill bit penetrates the cortical bone of the lesion, the inner needle is withdrawn, and only the outer needle advances. During the advancement of the outer needle, the serrations cut the bone marrow, and the cut bone marrow enters the sample receiving cavity. The outer needle is withdrawn, and the bone marrow sample is extracted, preserving the original appearance and structure of the bone marrow sample. A drainage connector is also provided. The outer needle is connected to a flushing device through the drainage connector, allowing for the injection of medication to treat and flush the bone lesion, or for the extraction of diseased bone marrow and waste fluid through a drainage device. The sample receiving cavity can also be cleaned through the drainage connector.

The invention discloses a bone marrow sample filtering device, a sample tube and a filtering method, and relates to the technical field of medical instruments.The bone marrow sample filtering device comprises an annular filtering frame and a filtering layer, and the outer side wall of the annular filtering frame can be in sealed contact with the inner side wall of the sample tube; the annular filter frame can axially move in the sample tube along the sample tube; the filter layer is fixedly arranged on the inner side of the annular filter frame, can shield the inner side space of the annular filter frame, and is matched with the annular filter frame to divide the interior of the sample pipe into an upper layer and a lower layer, so that the bone marrow sample solution is filtered. According to the bone marrow sample filtering device, the sample tube and the filtering method provided by the invention, the bone marrow sample filtering time is short, the efficiency is high, the operation is simple and convenient, and sample pollution is not easily caused.

The invention provides a primer probe group for detecting three leukemia fusion genes BCR-ABL1, ETV6-RUNX1 and TCF3-PBX1 and application of the primer probe group, and establishes a method for simultaneously detecting RNA of the three fusion genes based on capture and ligation reaction combined with multiple fluorescent quantitative PCR. The primer probe group comprises a capture probe, a connection probe, an amplification primer and a Taq-Man probe which are respectively used for detecting multiple types and reference genes of three fusion genes. Nucleic acid extraction and reverse transcription are not needed, target RNA in whole blood, dried blood spots or bone marrow samples can be directly split and captured, and three fusion genes are simultaneously detected in the same fluorescent quantitative PCR reaction system. The detection sensitivity is that the copy / reaction of BCR-ABL1 is 75, the copy / reaction of ETV6-RUNX1 is 6, and the copy / reaction of TCF3-PBX1 is 29.

This application discloses a method, apparatus, device, and storage medium for determining pathological indicators. The method includes: acquiring a bone marrow pathological image to be processed; preprocessing the bone marrow pathological image to obtain a set of bone marrow sample images; processing the set of bone marrow sample images to obtain a bone marrow tissue region image; processing the bone marrow tissue region image to determine the bone marrow adipose tissue region and trabecular bone tissue region, removing the bone marrow adipose tissue region and trabecular bone tissue region to obtain a processed bone marrow tissue image; inputting the processed bone marrow tissue image into a trained image segmentation model to obtain the bone marrow fibrous region; and statistically analyzing the degree of fibrosis based on the bone marrow tissue region image and the bone marrow fibrous region to determine pathological indicators. This method can extract the layout details of the pathological image, thereby enabling a more comprehensive and fine-grained statistical analysis of the degree of fibrosis and improving the accuracy of pathological indicator determination.

This invention relates to a method and system for analyzing complex cytokine exosomes in bone marrow and blood from elderly patients with hip fractures. The method includes bone marrow sample collection (predicting the degree of fibrosis and adjusting the collection volume), pretreatment (optimizing sample composition), dynamic gradient bone marrow digestion (adjusting enzyme ratios according to the fibrosis index and monitoring in multiple dimensions), exosome extraction (ultracentrifugation and nanofiltration), and complex cytokine exosome analysis (constructing a seven-dimensional matrix, etc.). The system consists of units for bone marrow sample collection, pretreatment, dynamic gradient bone marrow digestion, exosome extraction, and complex cytokine exosome analysis. This invention solves the problems of exosome damage and low separation efficiency in traditional methods, and has advantages such as increased exosome extraction volume, preservation of integrity, enhanced reliability of analytical results, and improved standardization and reproducibility.

The invention relates to a bone marrow blood composite cell factor exosome analysis method and system for hip fracture of old people. The method comprises the steps of bone marrow sample collection (pre-judging the fibrosis degree and adjusting the collection amount), pretreatment (optimizing sample composition), dynamic gradient bone marrow digestion (adjusting the enzyme proportion according to the fibrosis index and performing multi-dimensional monitoring), exosome extraction (ultracentrifugation and nanofiltration) and composite cell factor exosome analysis (constructing a seven-dimensional matrix and the like). The system is composed of a bone marrow sample collection unit, a pretreatment unit, a dynamic gradient bone marrow digestion unit, an exosome extraction unit and a composite cell factor exosome analysis unit. The method solves the problems of exosome damage and low separation efficiency of a traditional method, and has the advantages that the exosome extraction amount is increased, the integrity is protected, the reliability of an analysis result is enhanced, and the standardization and repeatability are improved.

The invention relates to the technical field of medicines, and provides application of zalcitabine in drugs for inhibiting and / or preventing and / or relieving and / or treating multiple myeloma in order to solve the problems that whether zalcitabine has anti-tumor activity in MM and related molecular mechanisms are not clear at present. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or relieving and / or treating multiple myeloma. The pharmaceutical preparation comprises an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is 2 ', 3'-dideoxycytidine. Researches show that zalcitabine induces mitochondrial dysfunction by targeted inhibition of expression of TFAM, and induces occurrence of ferroptosis of MM cells by triggering a cGAS-STING pathway through mtDNA cytoplasm stress. In-vivo animal experiments further show that zalcitabine can significantly slow down tumor growth. In addition, the antineoplastic activity of zalcitabine is also verified in a bone marrow sample derived from an MM patient.

The invention belongs to the field of biological pharmacy, and particularly discloses application of long-chain non-coding RNA lncRNA ALLHET (the sequence is shown as SEQ ID NO: 1) in diagnosis, treatment and prognosis evaluation of acute lymphocytic leukemia (ALL). The ALLHET expression quantity in a bone marrow sample is detected through qRT-PCR (Quantitative Reverse Transcription-Polymerase Chain Reaction) (primers are as shown in SEQ ID NO: 2-3), and the ALLHET expression quantity can be used as an ALL diagnostic marker after being obviously Prognostic analysis based on expression level grouping shows that the event-free survival rate (EFS) of a high expression group is remarkably reduced. Meanwhile, the ALLHET inhibitor can effectively inhibit ALL cell proliferation, promote apoptosis and block the cell cycle, and obviously inhibit tumor growth in an animal model. The invention provides a novel diagnostic target, a therapeutic drug and a prognosis evaluation system for ALL.